U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX18206498: GSM6721077: IVT_3hr_4_S34; Homo sapiens; RNA-Seq
1 ILLUMINA (NextSeq 2000) run: 9M spots, 2.7G bases, 929.1Mb downloads

External Id: GSM6721077_r1
Submitted by: FHCRC
Study: A genome-wide functional study of 3'UTR mutations in advanced prostate cancer [RNA-seq]
show Abstracthide Abstract
Metastatic, castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer with a high mortality rate due to a current lack of treatment options. While much is already known about how mutations in protein-coding sequences across the genome affect prostate cancer, somatic mutations occurring in the 3' untranslated regions (3'UTRs) of genes are largely unstudied. The 3'UTR is a genomic region that controls post-transcriptional gene expression through its recruitment of trans-acting factors such as RNA-binding proteins (RBPs) and microRNAs (miRNAs), which themselves are known to be oncogenes and tumor suppressors in many cases. To better understand the role of 3'UTR mutations across prostate cancer, we have created a database of 3'UTR somatic mutations in 185 patients with mCRPC, discovering 14,497 single-nucleotide mutations throughout the 3'UTRome. In order to functionally assay these variants, we have developed a novel pair of massively parallel reporter assays (MPRA) able to determine the effect of thousands of patient somatic mutations on post-transcriptional gene expression. In this two-pronged approach, we are able to measure whether each of 6,892 mutations found in recurrently mutated 3'UTRs affect mRNA stability, steady-state transcript level, and translation efficiency. This deep functional assessment of thousands of 3'UTR mutations allows us to uncover patterns in mutation functionality, including their association with RNA motifs and sequence conservation. Investigation into how the resultant gene expression changes from 3'UTR mutations affect prostate cancer pathogenesis, such as cancer growth or response to treatment, is also underway. This work represents an unprecedented view of the extent to which disease-relevant 3'UTR mutations affect mRNA stability, translation efficiency, and cancer phenotypes, expanding the boundaries of functional cancer genomics and potentially uncovering novel therapeutic targets in previously unexplored regulatory regions. Overall design: IVT RNASeq of samples
Sample: IVT_3hr_4_S34
SAMN31657569 • SRS15703660 • All experiments • All runs
Organism: Homo sapiens
Library:
Name: GSM6721077
Instrument: NextSeq 2000
Strategy: RNA-Seq
Source: TRANSCRIPTOMIC
Selection: cDNA
Layout: PAIRED
Construction protocol: After 10 minutes of incubation at room temperature, sample was spun at 20,000xg for 20 minutes at 4°C, then RNA pellet washed with fresh 75% ethanol before drying and resuspending in 40µL water. isolated mRNA was DNase treated using Turbo DNase in reactions consisting of 11µL (~15µg) RNA and 1.5µL Turbo DNase according to manufacturer's protocol. DNase-treated RNA was purified using lithium chloride precipitation as described in mMESSAGE mMACHINE T7 ULTRA Transcription Kit (Invitrogen). 2µg RNA per sample was reverse transcribed into cDNA using SuperScript III First-Strand Synthesis System (Invitrogen) and MPRA RNA-specific primer (Table **, primer #22).
Runs: 1 run, 9M spots, 2.7G bases, 929.1Mb
Run# of Spots# of BasesSizePublished
SRR222289239,014,0882.7G929.1Mb2023-03-13

ID:
25189470

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...